| Recruiting | 3 | 260 | Europe, Canada, Japan, RoW | Carboplatin-Paclitaxel, Dostarlimab | ARCAGY/ GINECO GROUP, GlaxoSmithKline | Endometrial Cancer | 04/26 | 10/29 | | |
PANDORA, NCT04083365: Capecitabine Plus Concomitant Radiation Therapy Followed by Durvalumab as Preoperative Treatment in Rectal Cancer |
|
|
| Recruiting | 2 | 100 | Europe | Capecitabine, Radiotherapy, Durvalumab | AUSL Romagna Rimini, AstraZeneca, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | RECTAL CANCER | 11/22 | 08/25 | | |
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers |
|
|
| Completed | 2 | 79 | Europe, Canada, US, RoW | Mirvetuximab soravtansine, MIRV, IMGN853 | AbbVie | Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 01/24 | 12/24 | | |
BRICKET, NCT06578559: Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC |
|
|
| Recruiting | 2 | 16 | Europe | Cetuximab, Encorafenib | Gruppo Oncologico del Nord-Ovest, Merck Sharp & Dohme LLC, Pierre Fabre Laboratories | Colorectal Cancer | 08/26 | 04/27 | | |
ERASE-CRC, NCT05062889: Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients |
|
|
| Recruiting | 2 | 477 | Europe | 5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5FU, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule, Oxaliplatin FOLFOX and FOLFOXIRI schedule, Oxa, Oxaliplatin CAPOX schedule, L-Leucovorin, Lederfolin, Capecitabine, Irinotecan, Trifluridine/Tipiracil, FTD/TPI, Trastuzumab, Tucatinib | Gruppo Oncologico del Nord-Ovest, Servier, Foundation Medicine, Seagen Inc. | Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer, RAS Wild-type Colon Cancer | 10/25 | 12/27 | | |
